In recent years, remarkable achievements have been made in the development of tyrosine kinase inhibitors (TKIs) that target KIT and/or platelet‐derived growth factor receptor α (PDGFRA); this has led to major clinical improvements and improved survival among advanced GIST patients.10, 11, 12, 13, 14, 15. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.